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ABST RACT
Aim. We aimed to assess the differences among various groups of drugs
users, especially in the psychiatric and psychological domains. Materials
and Methods. A retrospective study was carried out in collaboration with
C.E.T.T.T `St. Stelian` Institute from Bucharest. There were analyzed
the medical records of 604 hospitalized patients with heroin or polydrug
addiction. Results. Significant differences in diagnosis at submission
among groups were outlined (personality and behavior disorders, pvalue = .04298, psychotic disorders, p-value = .004274, schizophrenia,
p-value = .000141) as well as significant differences among psychiatric
parameters: perception (legal highs, opiates), attention (cannabis),
consciousness (legal highs), thinking (legal highs), and, instinctive life
(legal highs). Conclusions. Personality and behavioral disorders have
been particularly linked to opiate use, the psychotic disorder was related
to cannabis and legal highs intake, while schizophrenia was related to
legal highs intake.

Introduction
It is well known that once the onset of abuse substances,
some irreversible changes occur in one’s personality and
character. Due to the non-selective mechanism of action or
poly-consumption, most of the substances of abuse lead to
similar adverse effects, therefore the changes in one’s
psychological and psychiatric profile are similar.
However, given the fact that many of the changes
induced by the drugs of abuse are irreversible, most of the
consumers end up in the emergency room or detoxification
centers with various, non-specific psychological and
psychiatric symptoms, and at last, they end up in mental
health facilities. Although each class of drugs has certain
peculiarities when it comes to clinical symptoms, when it
comes to defining the addict’s profile from the psychiatric
and psychological perspectives, it is rarely possible to
conclude the type of drug that caused the illness.
Given the mechanisms of action of the various classes
of substances of abuse [1], the specificity of the different
types of consumption are described in Table 1.
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It should be noted that, due to the action on multiple
systems, the psychological and psychiatric profiles of
patients consuming various substances of abuse are usually
similar. To define some peculiarities of psychiatric profiles
of different groups of patients addicted to various classes
of substances of abuse, a retrospective study was
conducted in collaboration with C.E.T.T.T (Toxic
Addiction Assessment and Treatment Center for Young
People) „St. Stelian” detox center from Bucharest.

Materials and Methods
The study group consisted of 604 drug users, patients
who were voluntarily admitted to the detoxification center
C.E.T.T.T. `St. Stelian` of Bucharest due to their addiction
to different categories of drugs of abuse. Approved under
approval no. 1 issued on 25-Jan-2021 by the Ethics
Commission of the Center, the study includes medical data
of the patients which were collected by accessing the
center’s archive.
Analyzing the medical records, the following details
were taken into account: diagnosis at admission, primary
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diagnosis at discharge, admission symptoms, as well as
psychological and psychiatric examination.
The following indicators/ parameters were monitored:
age, sex, history of use of certain substances, diagnosis of
patients at admission, psychiatric and physical exam, as
well as psychological examination.
Statistical analysis
The data that was collected by analyzing the center’s
archive for a period of 6 years (January 2015 - January
2021) was centralized in an EXCEL database and

processed using the appropriate statistical functions for
each type of data collected. To assess the possible
correlations between various parameters, Chi test was
applied. The relationship between variables is described
using Chi-square test of independence, expressed as X2
(DF = degrees of freedom, N = sample size) = chi-square
statistic value, p = p-value. According to the requirements
of the Chi-square test of independence, parameters that had
less than 5 observations among the groups were excluded
from the analysis. For those situations with only 2 degrees
of freedom, the Yates correction was applied.

Table I. Correlation between mechanisms of action of the various classes of substances of abuse and psychiatric and
psychological manifestations.
Abuse substance

Mechanism of action

Psychiatric and psychological manifestations

Heroin and opiates
[2-5]

Action on opioid receptors: Miu
(µ1-3), Kappa (k1-2), Delta (δ1-2)

Antisocial behavior; compulsive drug use - drug
dependence; dysphoria (anti-reward effects); sedation;
agitation, insomnia; decreased appetite; euphoria;

Legal highs (New
Psychoactive
Substances - NPS)

Synthetic cannabinoids:
Action on CB1 and CB2
cannabinoid receptors

Agitation; irritability; confusion; slurred speech;
hallucinations; delusions; aggression and violent
behavior; delirium; paranoia; psychosis.

Synthetic cathinone:
Effects on the neurotransmitters:
monoamine, dopamine,
norepinephrine, and serotonin

Anxiety; agitation; panic; dysphoria; bizarre behavior;
psychosis; hallucinations, delirium.

Alcohol
[18-21]

Action on the gabaergic system
(GABA), opioidergic and
dopaminergic neurotransmitters,
and 5-HT3 receptor

Sedation; disinhibition; relaxation; pleasure; satisfaction;
compulsive drug use - drug dependence; euphoria;
psychosis; mental and physical dependence; insomnia;
agitation; hallucinations; visual illusions;

BZD
[22-25]

Action on GABA-mediated
inhibitory neurotransmission,
situses 1 and 2

Lethargy; slurred
decreased appetite.

Cannabis
[7-9,26-29]

Action on the CB1 and CB2
cannabinoid receptors

Euphoria; disinhibition; impaired thinking and
concentration; obsessions; delusions; hallucinations;
delirium; panic; psychosis; disorganized thinking;
psychotic symptoms; insomnia; disorientation; decreased
appetite; sleep disorders.

Amphetamines
[30-32]

Action on monoamines (MAO)

Altered consciousness; anxiety; psychosis; agitation;
increased intellectual strength; emotional instability;
personality changes; violent behavior; paranoid ideation.

Hallucinogenic
drugs (LSD)
[33,34]

Action on 5-HT1A, 5-HT2A, 5HT2C, dopamine D2, and α2
adrenergic receptors

Visual disturbances; synesthesia; psychotic states;
flashbacks; depersonalization; disorders of perception of
time and space; schizophrenia; suicidal tendencies; panic
attacks.

[6-13, 14-17]

Results
The study group consisted of 604 patients, who were
examined both psychologically (183) and psychiatrically
(421). The study group was composed of women and men,
aged between 18-46 years and 18-51 years, respectively.
The admission diagnosis of the patients was variable
depending on the symptomatology, they presented with
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speech;

irritability;

depression;

several behavioral disorders caused by drug consumption,
heroin addiction, cannabis addiction, major depressive
episode, to restlessness and agitation, mixed personality
disorder, and substance abuse, all of which were associated
or not with social problems. A complex description of the
group taking into account demographic aspects,
psychological and psychiatric examinations, and diagnoses
at admission is presented in Table 2.
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Table 2. Characterization of the study group
Parameter
Sex
Male/female ratio
Abuse substance
Age (years) (mean ± SD)

Group characteristics
87.25% male, 12.75% female
6.84
Heroin/opiates 13.08%; Legal highs 27.81%; Cannabis 11.26%; multiple drugs 46.03%;
other (alcohol, BZD, cocaine) 1.82%;
Psychiatric examination
Psychological examination
29.89 ± 6.65
male 29.89 ± 6.65 (range 18-51)
female 29.82 ± 6.65 (range 19-39)

27.14 ± 5.77
male 27.14 ± 5.77 (range 18-46)
female 27.08 ± 5.78 (range 18-34)

Psychological
examination

Total examinations 183: Cannabis 26 (11.26%), Legal highs 54 (29.51%), Opiates 23
(12.57%), Multiple drugs 76 (41.53%), others (alcohol, BZD, cocaine) 2.19%.
Changes in*: disease awareness 8.33%; attention 18.94%; perception 4.54%; memory
19.13%; thinking 10.04%; affectivity 14.39; activity 16.85%; personality 7.76%.
Total examinations 421: Cannabis 42 (9.98%), Legal highs 114 (27.08%), Opiates 56
Psychiatric examination
(13.30%), Multiple drugs 202 (47.98%), other (alcohol, BZD, cocaine) 1.66%.
Changes in*: perceptual function 10.34%; attention 19.74%; mnemonic function 13.28%;
TSO and allo-psychic 0.53%; consciousness 2.00%; thinking 11.81%; affectivity
16.63%; instinctive life 7.52%; nictemeral rate 18.16%.
Personality and behavior disorder: Cannabis 44.12%; Legal highs 47.02%; Opiates
Diagnosis at admission
63.29%; Multiple drugs 54.68%.
Moderate to major depressive episode: Cannabis 22.06%; Legal highs 14.29%; Opiates
17.72%; Multiple drugs 20.86%.
Psychotic disorder: Cannabis 35.29%; Legal highs 28.57%; Opiates 2.53%; Multiple
drugs 18.71%.
Schizophrenia: Cannabis 8.82%; Legal highs 13.69%; Opiates 2.53%; Multiple drugs
3.60%.
*Comparison applied for substances (Cannabis, legal highs, opiates, and multiple drugs)
Group characteristics
To outline the characteristics of the group, the
following demographic aspects were taken into account:
age at the time of admission, sex, and diagnosis at
admission. Also, highlights on the patterns of use were
outlined.
1. Indicator: age and sex
Out of the total of 604 patients included in the study,
there were 421 psychiatric examinations and 183
psychological examinations. The majority were men (527,
which represents 87.25%) and a small part were women
(77, representing 12.75%), the ratio of men/women being
6.84. Depending on the pattern of use, the distribution of
patients by sex was also outlined (Figure 1).
The mean age of the patients included in the study is
29.89 ± 6.65 years (29.89 ± 6.65 years for men, and 29.82
± 6.65 years for females) and ranged from 18 to 51 years
for the group (18-51 years for men, and 19-39 years for
females) on which psychiatric examination was analyzed.
As for the group which was analyzed under psychological
examination, the mean age is 27.14 ± 5.77 years,
27.14 ± 5.77 years (range 18-46) for men, and, 27.08 ± 5.78
(range 18-34) for females.

Figure 1. Abuse drug use distribution amongst the
groups depending on sex
2. Indicator: diagnosis at admission
There were taken into account the following diagnoses
at admission: personality and behavior disorder, moderate
to major depressive episode, psychotic disorder, and
schizophrenia (as presented in the Table 3). A Chi-square
test of independence was performed to examine the
relation between the substance of abuse (Cannabis,
Legal highs, Opiates, Multiple drugs) and various
diagnoses at submission. The results obtained for each
type of examination (psychological or psychiatric) is
described in Table 4.
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Daniela Ciucă Anghel et al.

Table 3. Distribution of different diagnoses at admission depending on the substance of abuse (psychological
examination/psychiatric examination/total examinations)
Personality and behavior
disorder

Moderate to major
depressive episode

Psychotic
disorder

Schizophrenia

Cannabis

13/17/30

8/7/15

9/15/24

1/5/6

Legal highs

20/59/79

8/16/24

18/30/48

7/16/23

Opiates

12/38/50

7/7/14

1/1/2

0/2/2

Multiple drugs

31/121/152

22/36/58

17/35/52

4/6/10

Table 4. Chi-static test: diagnosis at admission depending on the substance of abuse
Parameter

X2 (DF, N) = Chi-square statistic value, p-value count, (expected count),
[contribution to chi-square]

Personality and behavior
disorders

X2 (3, 593) = 8.1516, p value = .04298
Cannabis 30 (35.66) [0.90]; Legal highs 79 (88.11( [0.94]; Opiates 50 (41.43)
[1.77]; Multiple drugs 152 (145.80) [0.26].

Moderate to major depressive
episode

X2 (3, 593) = 4.1692, p value = .243761
Cannabis 15 (12.50) [0.50]; Legal highs 24 (30.88) [1.53]; Opiates 12 (14.52)
[0.44]; Multiple drugs 58 (51.10) [0.93].

Psychotic disorder

X2 (2, 514) = 10.9104, p value = .004274
Cannabis 24 (16.40) [3.52]; Legal highs 48 (40.53) [1.38]; Opiates 2 (NA);
Multiple drugs 52 (67.07) [3.38];

Schizophrenia

X2 (2, 484) = 17.7272, p value = .000141
Cannabis 6 (3.06) [2.82]; Legal highs 23 (13.54) [6.61]; Opiates 2 (NA);
Multiple drugs 10 (22.40) [6.86];

The result is significant at values of p-value < .05
3. Indicator: type of abuse substance
The study groups were characterized from the
perspective of the incriminated drug and the results were
outlined in Table 5.
Table 5. Distribution of different drug users among study
groups depending on the substance of abuse and the sex.
Substance of
abuse

M
(count, %)

F
(count, %)

Total

Heroin/opiates

75
(92.41 %)

4
(5.06 %)

79
(13.08 %)

Legal highs

148
(88.10 %)

20
(11.90 %)

168
(27.81%)

51
(75 %)

17
(25 %)

68
(11.26 %)

Multiple drugs

241
(86.69 %)

37
(13.31 %)

278
(46.03%)

Other (alcohol,
BZD, cocaine)

10
(90.91 %)

1
(9.09 %)

11
(1.82 %)

Cannabis

604
In the case of polyconsumption, from the total of 241
patients who combined different categories of drugs, 210
258

(87.13%) have associated legal highs (190 men and 20
women). Most patients have mentioned, „Pur”, and „Magic
White” as the most popular legal highs (known as New
Psychoactive Substances).
4. Assessment of mental state
• Psychiatric examination
To evaluate the psychiatric parameters, 414 psychiatric
examinations were analyzed for 4 groups of consumers:
Cannabis, legal highs, opiate, and polyconsumption
(multiple drugs). The other 7 examinations collected from
other drug users (such as alcohol, cocaine, BZD) were not
included in the analysis due to the very small frequency of
observations among the group.
The following parameters were analyzed: perceptual
function (hyperesthesia, hypoesthesia, anesthesia,
paresthesia, cenesthopathy, illusions, hallucinations),
attention (spontaneous, distribution-concentration, lability,
fatigue), mnemonic function (fixation, evocation,
hypermnesia, paramnesia), temporo-spatial orientation
TSO (self and allopsychic), consciousness (degree of
lucidity, changes in the structure of the field of
consciousness), thinking (rhythm, organization, coherence,
mental calculation, ideas, themes, delusional/depressive/
obsessive prevalence), affectivity (mood, emotions,

Psychological and psychiatric characterization of various groups of drugs users

feelings, intensity, lability, irascibility, anxiety, euphoria,
depression, parathymia), instinctive life (sexual instinct,
defense, food, maternal), nictemeral rhythm (waking
period, sleep period, sleep mode, sleep mode awakening,
depth, and duration of sleep, dreams, nightmares),
personality (deterioration, doubling, transformation).

A Chi-square test of independence was performed to
determine the existence of a possible correlation that is
statistically significant between the various changes in
psychiatric parameters and the category of the substance of
abuse (in this case Cannabis, legal highs, opiates, and
multiple drugs) (Table 6).

Table 6. CHI test - psychiatric parameter in correlation to substance abuse (Cannabis, legal highs, opiates, multiple
drugs).
Parameter
Perceptual function

Attention

Mnemonic function

Consciousness

Thinking

Affectivity

Instinctive life

Nictemeral rhythm

X2 (DF, N) = Chi-square statistic value, p value
count, (expected count), [contribution to chi-square]
X2 (3, 414) = 17.2647, p value = .000623
Cannabis 20 (17.86) [0.26]; legal highs 63 (48.46) [4.36]; multiple drugs 80 (85.87) [0.40];
opiates 13 (23.81) [4.91];
X2 (3, 414) = 9.5446, p value = .022861
Cannabis 40 (34.09) [1.03]; legal highs 95 (92.52) [0.07]; multiple drugs 161 (163.94)
[0.05]; opiates 40 (45.45) [0.65];
X2 (3, 414) = 3.3637, p value = .338878
Cannabis 20 (22.93) [0.37]; legal highs 69 (62.23) [0.74]; multiple drugs 110 (110.27)
[0.00]; opiates 27 (30.57) [0.00];
X2 (2, 358) = 7.1637. p value = .027824
Cannabis 5 (3.52) [0.62]; legal highs 15 (9.55) [3.11]; multiple drugs 10 (16.93) [2.83];
opiates 4 (NA);
X2 (3, 414) = 8.278, p value = .040602
Cannabis 24 (20.39) [0.64]; legal highs 63 (55.35) [1.06]; multiple drugs 95 (98.07) [0.10];
opiates 19 (27.19) [2.47];
X2 (3, 414) = 4.9036, p value = .178996
Cannabis 31 (28.71) [0.18]; legal highs 83 (77.93) [0.33]; multiple drugs 137 (138.08)
[0.01]; opiates 32 (38.28) [1.03];
X2 (3, 414) = 8.9039, p value = .030596
Cannabis 13 (12.90) [0.00]; legal highs 41 (35.25) [0.94]; multiple drugs 66 (62.45) [0.20];
opites 8 (17.31) [5.01];
X2 (3, 414) = 0.5862, p value = .899577
Cannabis 27 (27.29) [0.00]; legal highs 76 (74.07) [0.05]; multiple drugs 128 (131.25)
[0.08]; opiates 38 (36.39) [0.07];

The result is significant at values of p-value < .05
• Psychological examination
The second examination that was taken into account in
the characterization of the study group consisted of the
analysis of the examinations of 179 patients who
underwent a complete psychological examination. The
same as for psychiatric examination, the group of other
drug users (alcohol, cocaine, BZD) totalizing 4 patients
was excluded from the analysis. Almost similar to the
psychiatric examination, the analyzed parameters were:
disease
awareness
(present/absent),
attention
(concentrative hypoprosexia), perception (qualitative
disorders of perception), memory (fixation and/or
evocation
hypomnesia),
thinking
(delusional
ideas/suicide), affectivity (depressive mood), intellect
(according to/non-compliance with education), activity
(decreased useful performance), personality investigation
(low tolerance for frustration). A chi-square test of
independence was performed to determine the correlation

between the various changes in psychological parameters
and the substance of abuse consumed (Table 7).
Group characteristics
Most of the included patients in the study were men,
without notable differences between males and females
regarding the mean age at admission. Same, from the point
of view of the type of substance of abuse, almost similar
trends in consumption were outlined for both men and
women.
Diagnosis at admission
Regarding diagnosis at admission, according to the Chisquare test of independence, we conclude that personality
and behavior disorders are related to opiates consumption
while psychotic disorder is triggered especially by
Cannabis intake. Although the multiple drugs users group
appear to have a greater chi-static contribution than the rest
of the groups, given the fact that 87.13% of the users use
legal highs (New Psychoactive Substances) in
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polyconsumption, it can be concluded that legal highs users
are more likely to develop both schizophrenia and
psychotic disorder than the other users’ groups. As for the
depressive episodes, these seem to be common for all
categories of substances of abuse, the Chi-test showing up
that there is no significant relationship among them.

Assessment of mental state
The examination of the mental state (ESM) consists of
the formal evaluation of the thinking, of the disposition,
aiming at the current behavior of the patient [35]. The main
behavioral manifestations reported in the literature [2-34]
caused by some categories of drugs are presented in Table 8.

Table 7. CHI test – psychological parameter in correlation to abuse substance (Cannabis, legal highs, opiates, multiple
drugs)
Parameter
Disease awareness: absent

Attention: Concentrated
hypoprosexia
Perception: qualitative disorders

Memory: hypomnesia

Thinking: delusional
ideation/suicide

Affectivity: depressive mood

Activity: diminished useful yield

Personality: low tolerance for
frustration

X2 (DF, N) = Chi-square statistic value, p-value
count, (expected count), [contribution to chi-square]
X2 (2, 155) = 1.9161, p value = .383633
Cannabis 9 (6.71) [0.78]; legal highs 11 (13.94) [0.62]; multiple drugs 20
(19.35) [0.02]; opiates 4 (NA)
X2 (3, 178) = 2.0656, p value = .558912
Cannabis 13 (14.53) [0.16]; legal highs 34 (30.17) [0.49]; multiple drugs 42
(42.46) [0.00]; opiates 11 (12.85) [0.27];
X2 (1, 130) = 4.278, p value = .038609
- with Yates correction: X2 (1, 130) = 3.3362, p .067771
Cannabis 3 (NA); legal highs 13 (8.72) [2.1]; multiple drugs 8 (12.28) [1.49];
opiates 0 (NA);
X2 (3, 179) = 0.8581, p value = .835532
Cannabis 15 (14.67) [0.01]; legal highs 33 (30.47) [0.21]; multiple drugs 41
(42.88) [0.08]; opiates 12 (12.98) [0.07];
X2 (1, 130) = 14.8701, p value = .000115
correctio Yates: X2 (1, 130) = 13.4625, p .000243
Cannabis 4 (NA); legal highs 29 (18.69) [5.68]; multiple drugs 16 (26.31)
[4.04]; opiates 4 (NA);
X2 (3, 179) = 1.7581, p value = .064086
Cannabis 14 (11.04) [0.79]; legal highs 21 (22.93) [0.16]; multiple drugs 31
(32.27) [0.05]; opiates 10 (9.77) [0.01];
X2 (3, 179) = 2.7916, p value = .424884
Cannabis 13 (12.93) [0.00]; legal highs 30 (26.85) [0.37]; multiple drugs 38
(37.79) [0.00]; opiates 8 (11.44) [1.03];
X2 (1, 130) = 1.5997, p value = .205946
- with Yates correction: X2 (1, 130) = 1.1285, p .288099
Cannabis 3 (NA); legal highs 11 (14.12) [0.69]; multiple drugs 23 (19.88)
[0.49]; opiates 4 (NA)

The result is significant at values of p-value < .05
Table 8. Behavioral effects depending on the drug of abuse
Abuse substance

Behavioral effects

Heroin, methadone

Euphoria, drowsiness, loss of appetite, decreased sexual appetite,
decreased activity, personality changes
Euphoria, agitation, hyperactivity, aggression, irritability, paranoid
tendencies, decreased libido to impotence, visual and tactile
hallucinations

Amphetamines and other sympathomimetics
(including cocaine), amphetamine-like
substances (khat, methcathinone), designer
amphetamines (MDMA (ecstasy))
PCP (phencyclidine) and ketamine
Benzodiazepine CNS depressants
Alcohol
Cannabis
260

Hallucinations, paranoid ideas, lability, schizophrenia
Aggression with violent behavior, confusion, inattention, drowsiness,
convulsions
Euphoria, drowsiness, confusion, motor incoordination
Euphoria or dysphoria, anxiety, inappropriate laughter, panic
symptoms, psychosis, depression, apathy
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Discussion
Psychiatric examination
The relationship between variables proved to be
significant for the following parameters: perceptual
function, attention, consciousness, thinking, and instinctive
life. It turns out that legal highs and opiate consumer
groups are more likely to experience perceptual changes
such as hallucinations and paresthesia than other consumer
groups. The group of Cannabis users is significantly more
likely to suffer from attention deficit disorder, legal highs
users have a greater impact on disease awareness, and
opiate users are more likely to experience changes in
thinking and instinct conservation [1,3,36].
Changes in perception are hallucinations, illusions,
and perceptual distortions. Hallucinations can occur in any
sensory way, having no diagnostic significance (except for
taste/olfactory hallucinations and hallucinations that could
indicate an organic pathology in the brain). The occurrence
of these is not caused by external stimuli but they are
generated inside the CNS (central nervous system).
Illusions are the second category of perceptual changes.
These, unlike hallucinations, are triggered by an external
stimulus that is analyzed and misinterpreted [8,37-40].
According to the X2 quantum effects test X2 (3, 414) =
17.2647, p = .000623, the groups of opiates and legal highs
users are more likely to develop perceptual changes,
mostly hallucinations than the other groups.
In terms of changes in attention (orientation and
concentration of mental activity in a certain direction)
during the psychiatric examination, significant differences
were obtained between consumer groups, X2 (3, 414) =
9.5446, p-value = .022861. Manifested by the difficulty in
directing, concentrating, and mobilizing attention, global
hypoprosexia appears more significant among Cannabis
users. During the psychiatric examination, the global
hypoprosexia leads to the patient's distractibility, which
entails the need for the evaluator to repeat the questions [41].
The mnemonic function was evaluated in terms of
decreased, either concerning immediate memory or shortterm memory (recent) [42-44]. There were no significant
differences between the analyzed groups in changing this
parameter, X2 (3, 414) = 3.3637, p-value = .338878.
Consciousness refers to the patient's degree of
lucidity. Its modification consists of the misinterpretation
of the data from the environment. This can have
repercussions on attention span, temporal and spatial
orientation, and can generally affect vision [45-47].
Between the groups of consumers analyzed, a statistical
difference was obtained, X2 (2, 358) = 7.1637, p-value =
.027824, the polyconsumption contributing the majority to
the “blurring” of the field of consciousness. Legal high users
seem to be more likely to develop changes in consciousness
than Cannabis, multiple drugs users, or opiates [48-52].

Thinking can be impaired in the sense of slowing
down, ideas are disorganized and ideas of delirium and
grandeur predominate (the patient is perceived as superior).
Patients feel that they are being followed (the idea
of pursuit and persecution) [53-55]. Following the
significance test for quantum effects, there are significant
differences between consumer groups, X2 (3, 414) = 8.278,
p-value = .040602, with opiate users being more prone to
such manifestations than legal highs, Cannabis users, or
multiple drugs users.
In terms of affectivity, rapid and unpredictable mood
swings (between euphoric and depressive states, anxiety or
irritability) were noted [56]. There are no statistically
significant differences between consumer groups, X2 (3,
414) = 4.9036, p-value = .178996.
Possible changes in the instinctive life were analyzed
and it was found that lack of appetite predominates and
rarely there was a decrease in sexual appetite [57,58]. With
a dominant contribution to chi-square value and a
significant chi-square test X2 (3, 414) = 8.9039, p-value =
.030596, opiate use predisposes consumers to decrease
instincts.
Nictemeral rhythm disorders include a series of
hypnotic changes such as insomnia (total or partial),
insomnia manifested by fragmented sleep, or restless sleep
with nightmares [59]. As a result, daytime sleepiness can
occur, leading to a reversal of sleep-wake rhythm. From
this point of view, the significance test for quantum effects
does not show any significant differences between
consumer groups as the p-value in this care is >.05 (X2 (3,
414) = 0.5862, p-value = .899577).
Following the analysis of psychiatric examinations, it
was concluded that at the time of examination most
patients were temporally-spatially oriented (with some
situations of temporal disorientation), consciousness was
either altered or absent or with delusional content. The
thinking appears disorganized, with a mostly slow pace, the
predominant delusional ideas, of grandeur but also of
pursuit and persecution. From an emotional point of view,
there is lability, depression, irritability, anxiety, dysphoria,
feelings of worthlessness, and inner tension. Also, drugs
users manifest a decrease in instincts, in this case, a
decrease in food appetite, insomnia, and the personality is
changed in the context of the disease [60-62].
Psychological examinations
The relationship between the variables proved to be
significant for the "thinking" parameter. It turns out that the
legal highs consumer group is more likely to exhibit
changes in thinking such as delusional ideation or suicide
than other consumer groups [63,64]. According to the data
collected, we can outline a general clinical picture for drug
users: most patients have difficulty concentrating, in some
cases eye contact is difficult to establish, hypomnesia of
both fixation and evocation, their thinking and activity are
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directed to addiction problems and drug procurement,
highlighting their mental lability [65-67].

Conclusions
Following this study, there were outlined some
correlations between different categories of substances of
abuse and psychological and psychiatric parameters. Also,
the study outlines the main disorders that may appear after
legal highs intakes, such as psychotic disorder and
schizophrenia. These highlights can serve as support for
future research in the field. More research is needed in the
field to determine whether these changes in one’s
personality are irreversible or reversible (the patients
regaining their healthy mental state when they stop using
legal highs).
Given the fact that a comparison between patients’
mental health before and after abuse substances
consumption is not possible, the importance of this
retrospective study is significant as a prospective study
with healthy patients intended to use these types of drugs
would not be ethical. The study gives new perspectives on
outlining the correlation of variable parameters
(psychiatric, and psychological) with the possible chemical
structures of the incriminated drugs detected by highperformance analysis methods in future research studies.
Limitations
Analyzing the data that was collected, a few limitations
can be highlighted. First of all, the groups are unequal,
most of them being opiate addicts. Secondly, psychiatric
and psychological parameters were compared with the
normal reference values in the healthy individual, as the
mental health state of the included patients was not
available before admission to the center. Finally, the data
collected are not correlated with the chemical structures of
the incriminated drugs of abuse, as the study is
retrospective, and the information collected is based on the
patient’s confessions.

Highlights
✓

✓
✓

A wide range of symptoms appears after substances of
abuse intake because most drugs cause non-specific
symptoms, especially in the psychiatric and
psychological sphere.
Most the substances of abuse determine multiple
changes in the consumers’ personalities.
The collaboration between pharmacists, chemists, and
psychologists is essential in assessing a possible
correlation between the changes in one’s personality
and the specific chemical structures of different drugs.
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